Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 3 mg - tablet - excipient ingredients: magnesium stearate; lactose monohydrate; colloidal anhydrous silica; pregelatinised maize starch; sodium lauryl sulfate; microcrystalline cellulose; titanium dioxide; hypromellose; purified talc; quinoline yellow aluminium lake; macrogol 4000; macrogol 400 - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 2 mg - tablet - excipient ingredients: sodium lauryl sulfate; lactose monohydrate; colloidal anhydrous silica; microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; titanium dioxide; hypromellose; sunset yellow fcf aluminium lake; purified talc; macrogol 4000; macrogol 400 - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 1 mg - tablet - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; colloidal anhydrous silica; lactose monohydrate; magnesium stearate; sodium lauryl sulfate; titanium dioxide; propylene glycol; hypromellose; hyprolose; purified talc - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone, quantity: 0.5 mg - tablet - excipient ingredients: pregelatinised maize starch; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; sodium lauryl sulfate; lactose monohydrate; titanium dioxide; hypromellose; purified talc; macrogol 4000; iron oxide red; macrogol 400 - ozidal is indicated for - treatment of schizophrenia and related psychoses; short-term treatment of acute mania associated with bipolar 1 disorder; treatment (up to 12 weeks) of psychotic symptoms or persistent agitations or aggression unresponsive to non-pharmacological approaches in patients with moderate to severe dementia of the alzheimer type; treatment of conduct and other disruptive behaviour disorders in children (over 5 years), adolescents and adults with sub-average intellectual functioning or mental retardation in whom destructive behaviours (eg. aggression, impulsivity and self-injurious behaviours) are prominent; treatment of behavioural disorders associated with autism in children and adolescents.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - risperidone -

Australia - English - Department of Health (Therapeutic Goods Administration)

ranbaxy australia pty ltd - risperidone -

Ireland - English - HPRA (Health Products Regulatory Authority)

ucb (pharma) ireland limited - alprostadil - pdr+solv for soln for inj - 10 microgram/ml - drugs used in erectile dysfunction

Ireland - English - HPRA (Health Products Regulatory Authority)

ucb (pharma) ireland limited - alprostadil - pdr+solv for soln for inj - 20 microgram/ml - drugs used in erectile dysfunction

Ireland - English - HPRA (Health Products Regulatory Authority)

ucb (pharma) ireland limited - alprostadil - pdr+solv for soln for inj - 40 microgram/ml - drugs used in erectile dysfunction

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

advanz pharma - alprostadil - powder and solvent for solution for injection - 10microgram